RT Conference Proceedings
T1 ACTG-HIV symptoms changes in patients switched to RPV/FTC/TDF due to previous intolerance to CART. Interim analysis of the PRO-STR study.
A1 Podzamczer, Daniel
A1 Rozas, Nerea
A1 Domingo, Pere
A1 Ocampo, Antonio
A1 Van den Eynde, Eva
A1 Deig, Elisabeth
A1 Vergara, Antonio
A1 Knobel, Hernando
A1 Pasquau, Juan
A1 Antela, Antonio
A1 Crespo, Manuel
A1 Clotet, Bonaventure
A1 Muñoz, Jessica
A1 Fernandez, Pedro
A1 Geijo, Paloma
A1 Rodríguez de Castro, Eduardo
A1 Diz, Julio
A1 Casado, Araceli
A1 Torres, Covadonga
K1 Coinfección
K1 Estudios de seguimiento
K1 Infecciones por VIH
K1 Humanos
K1 Masculino
K1 Estudios prospectivos
K1 Calidad de vida
K1 Inhibidores de transcriptasa inversa
K1 Carga viral
AB INTRODUCTIONTolerability and convenience are crucial aspects for the long-term success of combined antiretroviral therapy (cART). The aim of this study was to investigate the impact in routine clinical practice of switching to the single tablet regimen (STR) RPV/FTC/TDF in patients with intolerance to previous cART, in terms of patients' well-being, assessed by several validated measures.METHODSProspective, multicenter study. Adult HIV-infected patients with viral load under 1.000 copies/mL while receiving a stable ART for at least the last three months and switched to RPV/FTC/TDF due to intolerance of previous regimen, were included. Analyses were performed by ITT. Presence/magnitude of symptoms (ACTG-HIV Symptom Index), quality of life (EQ-5D, EUROQoL & MOS-HIV), adherence (SMAQ), preference of treatment and perceived ease of medication (ESTAR) through 48 weeks were performed.RESULTSInterim analysis of 125 patients with 16 weeks of follow up was performed. 100 (80%) were male, mean age 46 years. Mean CD4 at baseline was 629.5±307.29 and 123 (98.4%) had viral load <50 copies/mL; 15% were HCV co-infected. Ninety two (73.6%) patients switched from a NNRTI (84.8% from EFV/FTC/TDF) and 33 (26.4%) from a PI/r. The most frequent reasons for switching were psychiatric disorders (51.2%), CNS adverse events (40.8%), gastrointestinal (19.2%) and metabolic disorders (19.2%). At the time of this analysis (week 16), four patients (3.2%) discontinued treatment: one due to adverse events, two virologic failures and one with no data. A total of 104 patients (83.2%) were virologically suppressed (<50 copies/mL). The average degree of discomfort in the ACTG-HIV Symptom Index significantly decreased from baseline (21±15.55) to week 4 (10.89±12.36) & week 16 (10.81±12.62), p<0.001. In all the patients, quality of life tools showed a significant benefit in well-being of the patients (Table 1). Adherence to therapy significantly and progressively increased (SMAQ) from baseline (54.4%) to week 4 (68%), p<0.001 and to week 16 (72.0%), p<0.001.CONCLUSIONSSwitching to RPV/FTC/TDF from another ARV regimen due to toxicity, significantly improved the quality of life of HIV-infected patients, both in mental and physical components, and improved adherence to therapy while maintaining a good immune and virological response.
PB BioMed Central
YR 2014
FD 2014-11-02
LK http://hdl.handle.net/10668/2007
UL http://hdl.handle.net/10668/2007
LA en
NO Podzamczer D, Rozas N, Domingo P, Ocampo A, Van den Eynde E, Deig E, et al. ACTG-HIV symptoms changes in patients switched to RPV/FTC/TDF due to previous intolerance to CART. Interim analysis of the PRO-STR study. J Int AIDS Soc. 2014; 17(4 Suppl 3):19814
NO Journal Article; Abstracts of the HIV Drug Therapy Glasgow Congress 2014.
DS RISalud
RD Apr 18, 2025